SGMO Sangamo Therapeutics Inc.

9.68
-0.02  -0%
Previous Close 9.7
Open 9.72
Price To Book 2.68
Market Cap 1,122,276,142
Shares 115,937,618
Volume 1,009,783
Short Ratio
Av. Daily Volume 1,163,062
Stock charts supplied by TradingView

NewsSee all news

  1. Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation

    The STEADFAST clinical study of TX200 is the first-in-human trial to evaluate a CAR-Treg cell therapy Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the United Kingdom's (UK)

  2. Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London,

  3. Sangamo Therapeutics Announces New Scientific Advisory Board

    Members include distinguished international experts across a diverse range of scientific and therapeutic areas Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that is has

  4. Sangamo Therapeutics Reports Third Quarter 2019 Financial Results

    Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business

  5. Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 presentation at ASH December 7, 2019, 5:30pm ET.
SB-525
Hemophilia A
Phase 1/2 presentation at ASH December 9, 2019, 6pm ET.
ST-400
beta-thalassemia
Next trial to be initiated in 2020.
SB-318
MPS Type 1
Phase 1/2 data to accumulate throughout 2019.
SB-FIX
Hemophilia B
Phase 1/2 ongoing with data to accumulate throughout 2019.
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 trial to be initiated 2019.
ST-920
Fabry disease
Phase 1/2 trial to be initiated in 2020.
TX200
Kidney transplantation

Latest News

  1. Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation

    The STEADFAST clinical study of TX200 is the first-in-human trial to evaluate a CAR-Treg cell therapy Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the United Kingdom's (UK)

  2. Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London,

  3. Sangamo Therapeutics Announces New Scientific Advisory Board

    Members include distinguished international experts across a diverse range of scientific and therapeutic areas Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that is has

  4. Sangamo Therapeutics Reports Third Quarter 2019 Financial Results

    Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business

  5. Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster

  6. Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019. Mr. Lee oversees

  7. Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November

  8. Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all

  9. Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that members of the management team will present at the following investor and industry conferences in October: Cell & Gene

  10. Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that management will present at the following investor conferences in September: Wells Fargo 2019 Healthcare